New: Medicovid-AG® SARS-CoV-2 rapid antigen test

With immediate effect, MEDICE markets a SARS-CoV-2 rapid antigen test, which expands the SARS-CoV-2 rapid test portfolio by adding to the SARS-CoV-2 rapid antibody test already introduced.

The rapid antigen test acts as a qualitative confirmation of an acute SARS-CoV-2 infection and identifies the specific antigen for SARS-CoV-2 in samples from the nasopharyngeal zone and sputum. The result is available within 20 to 30 minutes.

The rapid test meets all of the quality criteria: 100% specificity, 96% sensitivity, validated in clinical trials and CE-certified.

Infected individuals, especially those with a high viral load (superspreaders) can be identified and isolated in minutes. Due to the short sample-to-answer time and the high test frequency, chains of infection can be quickly broken and the outbreak of infection controlled.

Administration of the rapid test is simple and should be carried out by medical professionals. Please see the directions for use for details on administration of the test and interpretation of the results.

Download at: https://medice.com/de-de/service/downloads